What Is Jardiance 25 mg Used For and How It Works

Jardiance (empagliflozin) 25 mg is a prescription medication approved to treat type 2 diabetes, reduce the risk of cardiovascular death in people with type 2 diabetes and established heart disease, treat symptomatic chronic heart failure in adults, and slow kidney disease progression. It works by blocking a protein in the kidneys called SGLT2, which causes excess glucose to be flushed out through urine rather than reabsorbed into the bloodstream. That single mechanism sets off a cascade of effects that extend well beyond blood sugar control, which is why Jardiance’s list of approved uses has expanded considerably since it first reached the market as a diabetes drug.

How the SGLT2 Mechanism Actually Works

Your kidneys filter roughly 180 grams of glucose from your blood every day, then reabsorb almost all of it back into circulation. A protein called sodium-glucose co-transporter 2 handles about 90% of that reabsorption. Jardiance blocks this protein, so a meaningful portion of filtered glucose passes into your urine instead of being returned to your blood. The result is lower blood sugar without relying on insulin signaling, which makes it fundamentally different from older diabetes drugs that either push your pancreas to produce more insulin or make your tissues more sensitive to the insulin you already have.

Because the drug works in the kidneys rather than at the level of insulin, it produces several downstream effects. The glucose dragged into urine pulls water along with it through osmotic diuresis, which reduces blood volume and lowers blood pressure. That calorie loss from excreted glucose also contributes to modest weight reduction. Researchers have found that the blood-pressure-lowering effect goes beyond simple fluid loss, involving improvements in blood vessel function, reduced arterial stiffness, and decreased sympathetic nervous system activity.¹ The blood pressure drop persists even in people with impaired kidney function who aren’t excreting much extra glucose, which suggests the mechanism is more complex than a simple diuretic effect.²

There is also growing evidence that empagliflozin has direct anti-inflammatory and antioxidant effects on blood vessels, independent of its glucose-lowering activity. Studies show it can suppress inflammatory pathways and reduce oxidative stress in cardiovascular tissue, which may partially explain why the drug’s heart benefits seem disproportionately large compared to the modest improvement in blood sugar.³ Empagliflozin has been shown to reverse dysfunction in blood vessel cells through mechanisms that don’t depend on glucose transport at all.⁴

Why 25 mg Instead of 10 mg

Jardiance comes in two strengths: 10 mg and 25 mg. The standard approach is to start at 10 mg once daily and potentially increase to 25 mg if more blood sugar control is needed. For heart failure and chronic kidney disease indications, the 10 mg dose is typically the one studied and used, so the 25 mg dose is most relevant to people taking Jardiance primarily for type 2 diabetes.

The honest picture on dose differences is nuanced. A meta-analysis of randomized trials found that for lowering HbA1c (the key blood sugar marker), 25 mg ranked highest among tested doses, and that advantage became more apparent with use beyond 12 weeks.⁵ However, when you look at the absolute numbers, the gap between 10 mg and 25 mg is small. One pooled analysis found HbA1c reductions of about 0.61% with 10 mg versus 0.63% with 25 mg, a difference that wasn’t statistically meaningful.⁶ Real-world data confirms that both doses produce comparable improvement in blood sugar control.⁷

Where 25 mg may have a more noticeable edge is weight loss. A real-world study found that patients on 12.5 or 25 mg lost significantly more total and percentage body weight compared to those on 10 mg, and a higher fraction of the higher-dose group achieved normal HbA1c levels below 5.7%.⁸ So if your doctor moves you from 10 mg to 25 mg, it’s typically to squeeze out a bit more glucose excretion and weight loss rather than because 10 mg failed dramatically.

Cardiovascular Protection

The landmark trial that changed the trajectory of this drug was EMPA-REG OUTCOME, which enrolled people with type 2 diabetes who already had established cardiovascular disease. Empagliflozin became the first glucose-lowering drug to demonstrate a reduced risk of cardiovascular events in this high-risk population. Compared to placebo on top of standard care, empagliflozin cut the risk of cardiovascular death by 38%, reduced hospitalization for heart failure by 35%, and lowered the composite of major adverse cardiovascular events (cardiovascular death, heart attack, or stroke) by 14%.⁹ Those results were striking enough that the drug earned a specific label indication for reducing cardiovascular death, moving Jardiance from “diabetes drug with a nice side benefit” to “cardiovascular protective agent that also lowers blood sugar.”

The size of the heart benefit surprised researchers because the modest HbA1c improvement alone couldn’t explain it. The benefits appeared early in the trial, before blood sugar changes would have had time to prevent long-term vascular damage, pointing to those other mechanisms like fluid reduction, blood pressure lowering, and direct vascular protection described earlier.

Heart Failure Across the Spectrum

Jardiance’s expansion into heart failure treatment represents a genuinely different use case from diabetes management. The EMPEROR-Preserved trial studied empagliflozin in people with heart failure whose heart pumped relatively normally (preserved ejection fraction, the type of heart failure that has historically had very few effective treatments). Over roughly two years, empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by about 21% compared to placebo, driven mainly by fewer hospitalizations. Total heart failure hospitalizations dropped by 27%.¹⁰ Crucially, these effects held up regardless of whether the patient had diabetes, which is why Jardiance is now approved for heart failure in people who are not diabetic at all.

Across the full range of heart failure types, whether the heart pumps weakly, moderately, or relatively normally, empagliflozin has shown consistent benefit in reducing hospitalizations and cardiovascular death in patients already receiving standard heart failure therapies.¹¹ This breadth of evidence is unusual for a heart failure drug and reflects the fact that the mechanism appears to help the heart through pathways like reducing fluid overload and improving cardiac energy metabolism rather than through the specific heart muscle abnormality driving each subtype.

Kidney Disease Protection

The EMPA-KIDNEY trial established empagliflozin’s role in chronic kidney disease, enrolling over 6,600 patients with CKD at risk of progression.¹² The drug slowed the rate at which kidney function declined by about 50% compared to placebo, measured by the chronic slope of estimated glomerular filtration rate (eGFR), which is the standard gauge of how well your kidneys are filtering blood.¹³ Cutting the rate of kidney decline in half is a substantial result because even modest slowing can mean the difference between years of preserved function and progression to dialysis.

The kidney benefit is thought to arise from reduced pressure within the glomeruli (the kidney’s tiny filtering units). By blocking glucose and sodium reabsorption in the early part of the kidney tubule, Jardiance triggers a feedback mechanism that constricts the blood vessel feeding each glomerulus, reducing the harmful high pressure that drives CKD progression. This is why the kidney benefit applies broadly, not just to people with diabetic kidney disease.

Common Side Effects

Because Jardiance flushes glucose into your urine, it creates an environment where yeast and bacteria can thrive in the urinary and genital tracts. Genital yeast infections (thrush) are the most characteristic side effect, reported four to nine times more often in people taking SGLT2 inhibitors than in those on placebo in major trials. These infections are generally mild and respond to standard antifungal treatment.¹⁴ Urinary tract infections, somewhat surprisingly, don’t appear to be more common with empagliflozin; the EMPA-REG OUTCOME trial found nearly identical UTI rates in the drug and placebo groups (about 18% each).¹⁴

Other common side effects include increased urination (a predictable result of the drug’s osmotic diuretic effect), mild dehydration symptoms like dizziness upon standing, and occasional nausea. These are generally manageable with adequate fluid intake and tend to be most noticeable in the first few weeks of treatment.

Serious Risks Worth Knowing About

The most dangerous rare side effect is euglycemic diabetic ketoacidosis, a form of ketoacidosis that occurs even when blood sugar is normal or only mildly elevated. This is dangerous precisely because it’s easy to miss: the usual red flag for ketoacidosis is very high blood sugar, but with SGLT2 inhibitors, blood sugar can look reassuringly normal while acid levels in the blood are climbing to life-threatening levels. Risk factors include acute illness, reduced food intake, and decreasing or stopping insulin.¹⁵ Importantly, the risk can persist even after you’ve stopped taking the medication, since empagliflozin’s effects on metabolism don’t vanish instantly.¹⁶ This is why surgeons and anesthesiologists typically ask patients to stop SGLT2 inhibitors several days before elective surgery.

Another rare but serious concern is Fournier’s gangrene, a rapidly spreading soft-tissue infection of the genital or perineal area. Initially flagged only in people with type 2 diabetes, it is now recognized that this complication can also occur in patients taking empagliflozin for non-diabetic conditions like heart failure.¹⁷ While extremely uncommon, it requires immediate medical attention. Symptoms include tenderness, redness, or swelling in the genital area accompanied by fever.

How Jardiance Compares to Dapagliflozin

Dapagliflozin (Farxiga/Forxiga) is the other widely prescribed SGLT2 inhibitor with overlapping indications. Patients and doctors frequently ask whether one is better than the other. A network meta-analysis found the two drugs comparable for preventing heart failure hospitalization. Empagliflozin showed an advantage in reducing worsening heart failure, while dapagliflozin showed a lower rate of all-cause death. Neither drug significantly increased hypoglycemia risk.¹⁸ In practice, the choice between them often comes down to insurance coverage, cost, and your doctor’s familiarity rather than a clear clinical winner.

Liver Fat Reduction

One of the more interesting emerging findings is empagliflozin’s effect on fatty liver disease. A systematic review and meta-analysis found that empagliflozin significantly reduced liver stiffness (a marker of liver scarring), BMI, and insulin resistance in people with non-alcoholic fatty liver disease.¹⁹ A controlled trial showed empagliflozin reduced liver fat content by about 2.4 percentage points compared to a slight increase in the placebo group, and the benefit appeared in both people with and without diabetes. The reduction in liver fat correlated strongly with baseline fat content, weight loss, and improved insulin sensitivity, but did not track with fasting glucose or HbA1c changes.²⁰ This is noteworthy because fatty liver disease affects roughly a quarter of the global population, and there are still very few well-studied drug treatments for it. Jardiance isn’t approved for this indication, but the data keeps building.

Sticking with the Medication

A practical concern with any chronic medication is whether people actually keep taking it. SGLT2 inhibitors appear to have a meaningful advantage here. A large claims-based study found that about 61% of patients prescribed an SGLT2 inhibitor were still adherent after a year, compared to about 54% of patients on sulfonylureas (an older class of diabetes drugs). Persistence, meaning not abandoning the prescription entirely, was also higher: 76% versus 69%.²¹ The likely reasons include the once-daily dosing, the weight loss rather than weight gain that plagued older drugs, and the very low risk of hypoglycemia since the drug’s mechanism doesn’t push insulin levels up.

Cost-Effectiveness and Access

Jardiance is a brand-name medication and is not cheap out of pocket. But several health-economic analyses have found that, when you account for the hospitalizations and disease progression it prevents, the math works out favorably. In the chronic kidney disease setting, a French analysis found that the cost of empagliflozin treatment was completely offset by savings from avoided kidney failure events, meaning the drug paid for itself and then some.²² For heart failure with reduced ejection fraction, a U.S. analysis estimated that empagliflozin added to standard care produced 18% fewer heart failure hospitalizations and 6% fewer deaths over a lifetime horizon.²³ A Spanish analysis across the full spectrum of heart failure found the cost per quality-adjusted life year gained was well below standard willingness-to-pay thresholds.²⁴ Generic empagliflozin is beginning to enter markets in some countries, which should eventually make the access question less fraught for patients who face high copays or coverage restrictions.